Publications
47
Citations
2,755
Est. group size
~4
Recurring co-author estimate
Active years
36
Publishing since 1991
Typically publishes in teams of ~15 · 15% small-team papers (≤3 authors) · across 10 venues
- Abstract 5151: Design and synthesis of highly efficacious CRBN-based pan-KRAS degraders targeting cancers with KRAS G12D, G12V and G12C mutations
Cancer Research · 2026
- MD-4251: A First-in-Class Oral MDM2 Degrader Inducing Complete Tumor Regression with Single-Dose Administration
Journal of Medicinal Chemistry · 2025
- Novel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse model
Blood · 2025
- Fertility Assessment of Tectono-Magmatic Cycles in the Tres Cerrillos Prospect (Western Cordillera of Ecuador)
Economic Geology · 2025
- Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9
Journal of Medicinal Chemistry · 2024
- Targeting MDM2 for the development of a new cancer therapy: progress and challenges
Medicinal Chemistry Research · 2023
- Three Supplementary Tables and Supplementary Figures S1-S13 from SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
2023
- Three Supplementary Tables and Supplementary Figures S1-S13 from SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
2023
- Data from SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
2023
- Data from SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
2023
- Therapeutic Strategies to Activate p53
Pharmaceuticals · 2022
- Strategies for the drug discovery and development of taxane anticancer therapeutics
Expert Opinion on Drug Discovery · 2022
- Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression
Journal of Medicinal Chemistry · 2021
- Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin–MLL Interaction with Strong <i>In Vivo</i> Antitumor Activity
Journal of Medicinal Chemistry · 2020
- Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein–Protein Interaction
Journal of Medicinal Chemistry · 2019
- Journal of Medicinal Chemistry×10
- Cancer Research×3
- The Cambridge Structural Database×2
- Nature Immunology×1
- Angewandte Chemie International Edition×1
- Paramita Ray
Medicine · University of Michigan
- Sangeeta Jaiswal
Medicine · University of Michigan
- Dipankar Ray
Medicine · University of Michigan
- May San Martinho
Medicine · University of Michigan
- Shannon M. Lacy
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile